Rucaparib (AG-014699,PF-01367338)

Rucaparib (AG-014699, PF-01367338)は一種のPARP阻害剤で、無細胞試験でPARP1に作用する時のKi値が1.4 nMになって、残り8つPARPドメインにも結合親和力を表します。臨床3期。

価格 在庫  
USD 151 あり
USD 168 あり
USD 264 あり
USD 844 あり

Rucaparib (AG-014699,PF-01367338) 化学構造
分子量: 421.36

高品質保証

カスタマーフィードバック(6)

MSDS

製品説明

  • Compare PARP Inhibitors
    PARP製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 Rucaparib (AG-014699, PF-01367338)は一種のPARP阻害剤で、無細胞試験でPARP1に作用する時のKi値が1.4 nMになって、残り8つPARPドメインにも結合親和力を表します。臨床3期。
ターゲット PARP
IC50 1.4 nM (Ki) [1]
In vitro試験 Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. [1] [2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. [3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
BT-474 NYrEU4JmTnWwY4Tpc44hSXO|YYm= MXuwMlEwOS93MECvNVAxOCCwTR?= M4D1WYlvcGmkaYTzJHBCWlBiYXP0bZZqfHliYYSgd5RienSrbnegZ49v[2W{boTyZZRqd25ib3[gOVAxKG6P MWWyOVEzQDR3NR?=
BT474 M1;YOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXpeIY2ODBibl2= MmnCNVDjiJNzNdMg[C=> M{fTOJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> NUD2NY9rOjVzMki0OVU>
SKBR3 MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTo[oo2ODBibl2= M3WwblEx6oDVMUZCpIQ> MlrwdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> M2DBPFI2OTJ6NEW1
AU565 M{O5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTtOVAxKG6P NFLDV2cyOOLCk{G1xsBl NVXOcYpFemWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? NELQWHczPTF{OES1OS=>
EFM192A MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXW1NFAhdk1? NF7uNJUyOOLCk{G1xsBl M4S5cpJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> Ml[1NlUyOjh2NUW=
MDA-MB-231 MlLpSpVv[3Srb36gRZN{[Xl? MmezNVAwOjBxNECg{txO MknPNlQhcA>? NH3Yc5RqdmO{ZXHz[ZMheC2DS2SgcIV3\Wy|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3TES|I1PDJyMUWy
MDA-MB-231 M3n3dGNmdGxiVnnhZoltcXS7IFHzd4F6 NUPmWodSOC5zLUSwJO69VQ>? MnHkNlQhcA>? NXHBOWV2UUN3MPMAjV3jiIlzNz63O:Kh|ryP M3q0eFI1PDJyMUWy
MDA-MB-231 MXzBdI9xfG:|aYOgRZN{[Xl? M2TlOFExNzJyL{SwJO69VQ>? MVeyOEBp MVLpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NWHsSlN7OjR2MkCxOVI>
MDA-MB-231 M4LZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUixNE8zOC92MDFOwG0> M2\5RVI1KGh? NFX0Z|ljdG:la4OgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCrbjDHNk9OKHCqYYPl NVPPZpFzOjR2MkCxOVI>
H460 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\GWoRmPDByIH7N M1zMO|I1yqCq M2LKXYlv[3KnYYPld{Bk\WyudXzhdkBz[WSrb4PlcpNqfGm4aYT5 NFO5ZYwzPDRzMU[xNS=>
A549  NW\DPGNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7lPHI1ODBibl2= MkX5NlTDqGh? NFfMUGNqdmO{ZXHz[ZMh[2WubIXsZZIhemGmaX;z[Y5{cXSrdnn0fS=> MVGyOFQyOTZzMR?=
DT40 NXS3R5Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmizTWM2OD1{MTDuUS=> MXuyOFM2PjhzMx?=
DU145 M1K1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;ERmdHUUN3ME2xPEBvVQ>? NG\kSnQzPDN3NkixNy=>
COLO704 NYLuUHZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13N[mlEPTB;Mj61NkDDuSByLk[3JO69VQ>? MmLENlM4Ojl2MEK=
OVMANAb Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[2N|ZKSzVyPUKuOVghyrFiMD6zPEDPxE1? NVTacphiOjN5Mkm0NFI>
OV177 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJwN{igxtEhOC55MTFOwG0> MlTCNlM4Ojl2MEK=
OAW28 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu2eo5KSzVyPUOuOlEhyrFiMD6yPEDPxE1? NFjNTFYzOzd{OUSwNi=>
OVSAHO MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;6cZJpUUN3ME2zMlY1KMLzIECuN|Mh|ryP M3zUVFI{PzJ7NECy
OVKATE NEm5fVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNwNkSgxtEhOS55OTFOwG0> MV2yN|czQTRyMh?=
OVCAR3 M3zTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rZOWlEPTB;Mz63OEDDuSByLkSwJO69VQ>? MkXSNlM4Ojl2MEK=
PEO14 NFToRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTNwOESgxtEhOC55NjFOwG0> MX[yN|czQTRyMh?=
A2780 MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDSTWM2OD1|Lkm0JOKyKDBwMkWg{txO MVOyN|czQTRyMh?=
OVTOKO NIe2O|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLzWYU6UUN3ME20MlE1KMLzIEGuOVMh|ryP NYe2PI8{OjN5Mkm0NFI>
KURAMOCHIb NYTY[XBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHFTWM2OD12LkO0JOKyKDBwMkmg{txO NIjze2EzOzd{OUSwNi=>
TOV21G MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXZXYlKSzVyPUWuNFchyrFiMT6zNEDPxE1? MlezNlM4Ojl2MEK=
OVISE NIDqXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTVwNkigxtEhOC5{MzFOwG0> NV;BO4V3OjN5Mkm0NFI>
KK MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DwOWlEPTB;Nj6xOUDDuSBzLkSyJO69VQ>? NG\Wb4IzOzd{OUSwNi=>
RMUGS NWj2PYdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XUfGlEPTB;Nz6wN{DDuSBzLkizJO69VQ>? MYOyN|czQTRyMh?=
PEO6 Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTdwME[gxtEhOC55NDFOwG0> MWiyN|czQTRyMh?=
OVCA429 NFrVNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\SZ2lEPTB;OD6yPUDDuSBzLk[0JO69VQ>? MWiyN|czQTRyMh?=
OV167 NHmybFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWOzXWNxUUN3ME24MlM{KMLzIEGuNVgh|ryP Mo\lNlM4Ojl2MEK=
RMG1 NEKxdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nCd2lEPTB;OT6zNkDDuSB{LkO2JO69VQ>? Mk\rNlM4Ojl2MEK=
OVCAR5 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTlwNUCgxtEhOi53OTFOwG0> NHrsbIMzOzd{OUSwNi=>
EFO21 M2nZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36wcWlEPTB;OT65NkDDuSBzLki3JO69VQ>? MnWzNlM4Ojl2MEK=
ES2 NHPnUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFyLkGyJOKyKDFwMkOg{txO NWfzN3p2OjN5Mkm0NFI>
Tyk-nu Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3tOphUUUN3ME2xNE4zOCEEsTCxMlEzKM7:TR?= MkTINlM4Ojl2MEK=
CAOV3 M4r4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPs[IlKSzVyPUGwMlM4KMLzIECuPFch|ryP NVnNTIJmOjN5Mkm0NFI>
OV207 NILPZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF{LkK3JOKyKDBwM{Kg{txO NHPXboczOzd{OUSwNi=>
HEY NUnqfGFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF|LkCxJOKyKDBwN{Wg{txO MlPjNlM4Ojl2MEK=
DOV13 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRjF3IN88US=> MYeyN|czQTRyMh?=
EFO27 Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLxWWFxUUN3ME6xOUDPxE1? MXiyN|czQTRyMh?=
HEY C2 MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XHbWlEPTB-MUWg{txO M1Hxb|I{PzJ7NECy
KOC-7cc NH\0SYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHafYhtUUN3ME6xOUDPxE1? MWmyN|czQTRyMh?=
MCASb M4PXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvlTWM2OD5zNTFOwG0> NGfYS2kzOzd{OUSwNi=>
OAW42 M1H1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{myUmlEPTB-MUWg{txO M3rMV|I{PzJ7NECy
OV2008 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRjF3IN88US=> M2rVO|I{PzJ7NECy
OV90 Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nHeWlEPTB-MUWg{txO M1zsdVI{PzJ7NECy
OVCA420b NE\1eXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXQS2tuUUN3ME6xOUDPxE1? NHjwR4IzOzd{OUSwNi=>
OVCA432 NEm0bJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7EdVg3UUN3ME6xOUDPxE1? M1;XSFI{PzJ7NECy
PEA2 NFTlUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRjF3IN88US=> NGjUfnEzOzd{OUSwNi=>
SKOV3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkCyTWM2OD5zNTFOwG0> NGrBWo0zOzd{OUSwNi=>
TOV112D MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[wMVMh|ryP M{PU[GlEPTB-MUWg{txO MVWyN|czQTRyMh?=
C4-2 NVrlfottT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPRNE0{KM7:TR?= NV7kW|N5OTRiZB?= MW\EUXNQ MVHk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 Mn3VNlM2PjV{NES=
PC3 NWXsSWp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVywMVMh|ryP M1jMR|E1KGR? M37KcmROW09? NX7jNpY3\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= M4fITFI{PTZ3MkS0
DU145 M1LiO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr6NE0{KM7:TR?= MkHnNVQh\A>? NIPzN|hFVVOR MYPk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 NWG1eVAyOjN3NkWyOFQ>
VCaP  Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\oNE0{KM7:TR?= M2fyNVE1KGR? NEDxXYxFVVOR M4m4[oRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? MXKyN|U3PTJ2NB?=
LNCaP  Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT5N|FHOC1|IN88US=> NYrHfpVEOTRiZB?= Mnz5SG1UVw>? M2izbIRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? NV;4b3RDOjN3NkWyOFQ>
MDA-MB-468 NFzVN5dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlXtTWM2OD17Lkeg{txO MWOyNlY4QDF4MR?=
MDA-MB-231 M{\1WGNmdGxiVnnhZoltcXS7IFHzd4F6 NVf6b4x1UUN3ME2xN{DPxE1? MnPjNlI3PzhzNkG=
Cal-51 M{G5W2NmdGxiVnnhZoltcXS7IFHzd4F6 NYf4XnhSUUN3ME24MlYh|ryP M1;uWVIzPjd6MU[x

... Click to View More Cell Line Experimental Data

In vivo試験 Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. [4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. [5]
臨床試験 Rucaparib is currently in Phase II clinical trials for locally advanced/metastatic breast or advanced ovarian cancer.
特集 The first PARP inhibitor used in clinical trials combined with temozolomide.

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Ki Determination Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.
Inhibition of PARP activity Inhibition of PARP activity in 5 × 103 D283Med cells is measured using various concentrations of Rucaparib (0-1 μM), compared with DMSO-only. Maximally stimulated PARP activity is measured in samples of permeabilised cells by immunologica

細胞アッセイ: [4]

細胞株 D425Med, D283Med and D384Med cells
濃度 0.4 μM
反応時間 3 or 5 days
実験の流れ Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 103, 3 × 103 and 3 × 103, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone.

動物実験: [4]

動物モデル CD-1 nude mice bearing established D283Med xenografts
製剤 Normal saline
投薬量 1 mg/kg
投与方法 One or four daily by i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rucaparib (AG-014699,PF-01367338) SDF
分子量 421.36
化学式

C19H18FN3O.H3PO4

CAS No. 459868-92-9
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 84 mg/mL (199.35 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 8-fluoro-5-(4-((methylamino)methyl)phenyl)-3,4-dihydro-2H-azepino[5,4,3-cd]indol-1(6H)-one phosphoric acid

文献中の引用 (14)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PARP 阻害剤

  • G007-LK

    G007-LKは一種の有効的で、選択性タンキラーゼ(tankyrase)阻害剤で、TNKS1/2に作用する時のIC50値が46 nM と 25 nMに分かれます。

  • NU1025

    NU1025は一種の有効なPARP阻害剤で、このIC50値が 400 nMです。

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • Blasticidin S HCl

    Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.

  • Olaparib (AZD2281, Ku-0059436)

    Olaparib (AZD2281, Ku-0059436)は一種の選択性PARP1/2阻害剤で、無細胞試験でIC50値が 5 nM/1 nMになって、PARP1/2に作用する効果は tankyrase-1に作用する効果が300倍が高くなります。臨床3期。

    Features:A potent PARP inhibitor (currently in late stage clinical trials).

  • Veliparib (ABT-888)

    Veliparib (ABT-888) は一種の有効なPARP1とPARP2阻害剤で、無細胞試験でKi値が5.2 nM と2.9 nMに分かれて、SIRT2に活性を表しません。臨床3期。

    Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.

  • Talazoparib (BMN 673)

    Talazoparib (BMN 673)は一種の新たなPARP阻害剤で、無細胞試験でIC50値が0.58 nMになります。Talazoparib (BMN 673)も一種の有効なPARP-2阻害剤ですが、PARGを抑制しなくて、PTEN突然変異型に高度敏感をしています。臨床3期。

    Features:Most potent and selective PARPi reported thus far.

  • Iniparib (BSI-201)

    Iniparib (BSI-201)は一種のPARP1阻害剤で、三種陰性乳癌(TNBC)に作用効果を持っています。臨床3期。

  • PJ34 HCl

    PJ34 HClはPJ34の塩酸塩形式で、一種のPARP阻害剤です。PJ34 HClはEC50値が20 nMになって、 PARP1/2に同等有効に作用します。

    Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).

最近チェックしたアイテム

Tags: Rucaparib (AG-014699,PF-01367338)を買う | Rucaparib (AG-014699,PF-01367338)供給者 | Rucaparib (AG-014699,PF-01367338)を購入する | Rucaparib (AG-014699,PF-01367338)費用 | Rucaparib (AG-014699,PF-01367338)生産者 | オーダーRucaparib (AG-014699,PF-01367338) | Rucaparib (AG-014699,PF-01367338)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ